444 related articles for article (PubMed ID: 27203857)
41. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
42. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
43. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Liu CH; Chen YS; Wang SS; Liu CJ; Su TH; Yang HC; Hong CM; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2018 Jan; 66(2):289-292. PubMed ID: 29020359
[TBL] [Abstract][Full Text] [Related]
44. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
45. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
[TBL] [Abstract][Full Text] [Related]
46. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Pérez-Pitarch A; Guglieri-López B; Ferriols-Lisart R; Merino-Sanjuán M
Int J Antimicrob Agents; 2016 Mar; 47(3):184-94. PubMed ID: 26915476
[TBL] [Abstract][Full Text] [Related]
47. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
48. Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
Sawinski D; Patel N; Appolo B; Bloom R
Transplantation; 2017 May; 101(5):968-973. PubMed ID: 27495759
[TBL] [Abstract][Full Text] [Related]
49. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
51. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
52. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Surendra M; Raju SB; Sridhar N; Vijay Kiran B; Rajesh G; Anvesh G; Raju N
Hemodial Int; 2018 Apr; 22(2):217-221. PubMed ID: 28972699
[TBL] [Abstract][Full Text] [Related]
53. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
Perumpail RB; Wong RJ; Ha LD; Pham EA; Wang U; Luong H; Kumari R; Daugherty TJ; Higgins JP; Younossi ZM; Kim WR; Glenn JS; Ahmed A
Transpl Infect Dis; 2015 Apr; 17(2):275-8. PubMed ID: 25641426
[TBL] [Abstract][Full Text] [Related]
54. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
[TBL] [Abstract][Full Text] [Related]
55. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Lin T; Wang X; Gao H; Feng Z; Xu L; Ma J; Li Z; Zhang L; Huang R; Liang X; Liu S
Blood Purif; 2020; 49(6):692-699. PubMed ID: 32289799
[TBL] [Abstract][Full Text] [Related]
56. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Sarrazin C; Buggisch P; Mauss S; Müller T; Zimmermann T; Klinker H; Pathil-Warth A; Schlag M; Nalpas C; Wegner S; Lonjon-Domanec I; Simon KG
Z Gastroenterol; 2019 May; 57(5):584-592. PubMed ID: 31083746
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
[TBL] [Abstract][Full Text] [Related]
58. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
59. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience.
Araujo A; Valenzuela-Granados V; Lopes AB; Michalczuk MT; Mantovani A; Alvares-da-Silva MR
Ann Hepatol; 2019; 18(3):450-455. PubMed ID: 31028014
[TBL] [Abstract][Full Text] [Related]
60. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
